Publications & Reports

Technology evaluation: R-1549, Antisoma/Roche.

Xing PX
Austin Research Institute, Studley Rd, Heidelberg, Vic 3084, Australia. px.xing@ari.unimelb.edu.au

Abstract

R-1549 (formerly known as pemtumomab), a murine monoclonal antibody (HMFG1) specific for the cancer antigen PEM and radiolabeled with yttrium-90, is under development by Antisoma and Roche as a potential treatment for ovarian and gastric cancer. In July 2003, enrollment for a phase III trial in ovarian cancer was completed.

Publication

  • Journal: Current Opinion in Molecular Therapeutics
  • Published: 01/10/2003
  • Volume: 5
  • Issue: 5
  • Pagination: 560-565